• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Section Contents Menu

  • News & Events
    -

    New and Generic Drug Approvals

    Visit Drugs@FDA to Search Drug Approval Reports by Month

    We have changed the format of this page. You will now find approvals listed under the date of the action, rather than the date we added the information to the website.

     

    May 18, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Butoconazole Nitrate butoconazole nitrate Cream; Vaginal Perrigo Israel Approval
    Epzicom abacavir sulfate; lamivudine Tablet; Oral Viiv Hlthcare Labeling Revision
    Lansoprazole lansoprazole Capsule, Delayed Rel Pellets; Oral Dr Reddys Labs Ltd Approval
    Lansoprazole lansoprazole Capsule, Delayed Rel Pellets; Oral Perrigo R and D Approval
    Lansoprazole lansoprazole Capsule, Delayed Rel Pellets; Oral Wockhardt Ltd Approval
    Levemir insulin detemir recombinant Injectable; Subcutaneous Novo Nordisk Inc Efficacy Supplement with Clinical Data to Support
    Trizivir abacavir sulfate; lamivudine; zidovudine Tablet; Oral Viiv Hlthcare Labeling Revision
    Ziagen abacavir sulfate Tablet; Oral Viiv Hlthcare Labeling Revision
    Ziagen abacavir sulfate Solution; Oral Viiv Hlthcare Labeling Revision

     

    May 17, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Actoplus Met metformin hydrochloride; pioglitazone hydrochloride Tablet; Oral Takeda Global Efficacy Supplement with Clinical Data to Support
    Actoplus Met metformin hydrochloride; pioglitazone hydrochloride Tablet; Oral Takeda Global Labeling Revision
    Actoplus Met Xr metformin hydrochloride; pioglitazone hydrochloride Tablet, Extended Release; Oral Takeda Global Labeling Revision
    Actos pioglitazone hydrochloride Tablet; Oral Takeda Pharms Usa Labeling Revision
    Avagard alcohol; chlorhexidine gluconate Solution; Topical 3m Labeling Revision
    Chg Scrub chlorhexidine gluconate Solution; Topical Ecolab Labeling Revision
    Chlorascrub Maxi Swabstick chlorhexidine gluconate; isopropyl alcohol Swab; Topical Prof Dspls Labeling Revision
    Chlorascrub Swab chlorhexidine gluconate; isopropyl alcohol Swab; Topical Prof Dspls Labeling Revision
    Chlorascrub Swabstick chlorhexidine gluconate; isopropyl alcohol Swab; Topical Prof Dspls Labeling Revision
    Cida-Stat chlorhexidine gluconate Solution; Topical Ecolab Labeling Revision
    Clopidogrel Bisulfate clopidogrel bisulfate Tablet; Oral Apotex Inc Approval
    Clopidogrel Bisulfate clopidogrel bisulfate Tablet; Oral Teva Approval
    Clopidogrel Bisulfate clopidogrel bisulfate Tablet; Oral Mylan Pharms Inc Approval
    Clopidogrel Bisulfate clopidogrel bisulfate Tablet; Oral Roxane Approval
    Clopidogrel Bisulfate clopidogrel bisulfate Tablet; Oral Sun Pharma Global Approval
    Clopidogrel Bisulfate clopidogrel bisulfate Tablet; Oral Aurobindo Pharma Ltd Approval
    Clopidogrel Bisulfate clopidogrel bisulfate Tablet; Oral Teva Pharms Approval
    Clopidogrel Bisulfate clopidogrel bisulfate Tablet; Oral Torrent Pharms Ltd Approval
    Clopidogrel Bisulfate clopidogrel bisulfate Tablet; Oral Dr Reddys Labs Ltd Approval
    Clopidogrel Bisulfate clopidogrel bisulfate Tablet; Oral Gate Pharms Approval
    Duetact glimepiride; pioglitazone hydrochloride Tablet; Oral Takeda Global Labeling Revision
    Lotensin benazepril hydrochloride Tablet; Oral Novartis Labeling Revision
    Pertzye pancrelipase Capsule, Delayed Release; Oral Digestive Care, Inc Approval
    Ropinirole Hydrochloride ropinirole hydrochloride Tablet, Extended Release; Oral Actavis Approval

     

    May 16, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Atomoxetine Hydrochloride atomoxetine hydrochloride Capsule; Oral Apotex Inc Tentative Approval
    Kaletra lopinavir; ritonavir Solution; Oral Abbott Labeling Revision
    Kaletra lopinavir; ritonavir Tablet; Oral Abbott Labeling Revision

     

    May 15, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Lamivudine and Zidovudine lamivudine; zidovudine Tablet; Oral Lupin Ltd Approval
    Lamivudine and Zidovudine lamivudine; zidovudine Tablet; Oral Aurobindo Pharma Ltd Approval

     

    May 11, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Anastrozole anastrozole Tablet; Oral Apotex Inc Approval
    Cetirizine Hydrochloride cetirizine hydrochloride Syrup; Oral Silarx Approval
    Fabior tazarotene Foam; Topical Stiefel Labs Inc Approval
    Morphine Sulfate morphine sulfate Tablet, Extended Release; Oral Ranbaxy Labs Ltd Approval
    Protonix pantoprazole sodium Tablet, Delayed Release; Oral Wyeth Pharms Inc Labeling Revision
    Protonix pantoprazole sodium For Suspension, Delayed Release; Oral Wyeth Pharms Inc Labeling Revision
    Zosyn piperacillin sodium; tazobactam sodium Injectable; Injection Wyeth Pharms Inc Labeling Revision
    Zosyn In Plastic Container piperacillin sodium; tazobactam sodium Injectable; Injection Wyeth Pharms Inc Labeling Revision

      

    May 10, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Carbidopa, Levodopa and Entacapone carbidopa; entacapone; levodopa Tablet; Oral Sun Pharma Global Approval
    Prolia denosumab Injectable; Subcutaneous Amgen Labeling Revision
    Protonix Iv pantoprazole sodium Injectable; Iv (Infusion) Wyeth Pharms Inc Labeling Revision
    Xgeva denosumab Injectable; Subcutaneous Amgen Labeling Revision
    Xolegel ketoconazole Gel; Topical Aqua Pharms Labeling Revision

     

    May 9, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Acetazolamide Sodium acetazolamide sodium Injectable; Injection Sagent Strides Approval
    Gilenya fingolimod Capsule; Oral Novartis Labeling Revision
    Revlimid lenalidomide Capsule; Oral Celgene Labeling Revision

     

    May 8, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Aciphex rabeprazole sodium Tablet, Delayed Release; Oral Eisai Inc Labeling Revision

     

    May 4, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Lamotrigine lamotrigine Tablet; Oral Glenmark Generics Approval

     

    May 3, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Avastin bevacizumab Vial; Intravenous Genentech Supplement
    Biaxin clarithromycin Tablet; Oral Abbott Labeling Revision
    Biaxin clarithromycin For Suspension; Oral Abbott Labeling Revision
    Biaxin Xl clarithromycin Tablet, Extended Release; Oral Abbott Labeling Revision
    Dexilant dexlansoprazole Capsule, Delayed Release; Oral Takeda Pharms Labeling Revision
    Escitalopram Oxalate escitalopram oxalate Solution; Oral Taro Approval
    Imodium A-D loperamide hydrochloride Tablet; Oral Mcneil Cons Labeling Revision
    Imodium Multi-Symptom Relief loperamide hydrochloride; simethicone Tablet; Oral Mcneil Cons Labeling Revision
    Prevacid lansoprazole Capsule, Delayed Rel Pellets; Oral Takeda Pharms Usa Labeling Revision
    Prevacid lansoprazole Tablet, Delayed Release, Orally Disintegrating; Oral Takeda Pharms Usa Labeling Revision
    Teflaro ceftaroline fosamil Powder; Iv (Infusion) Cerexa Manufacturing Change or Addition
    Vardenafil Hydrochloride vardenafil hydrochloride Tablet; Oral Teva Pharms Approval
    Zaditor ketotifen fumarate Solution/Drops; Ophthalmic Alcon Pharma Labeling Revision
    Zarontin ethosuximide Capsule; Oral Parke Davis Labeling Revision

     

    May 2, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Effexor venlafaxine hydrochloride Tablet; Oral Wyeth Pharms Inc Labeling Revision
    Effexor Xr venlafaxine hydrochloride Capsule, Extended Release; Oral Wyeth Pharms Inc Labeling Revision
    Stelara ustekinumab Injectable; Injection Centocor Ortho Biotech Inc Supplement
    Ultravist (Pharmacy Bulk) iopromide Injectable; Injection Bayer Hlthcare Labeling Revision
    Ultravist 150 iopromide Injectable; Injection Bayer Hlthcare Labeling Revision
    Ultravist 240 iopromide Injectable; Injection Bayer Hlthcare Labeling Revision
    Ultravist 300 iopromide Injectable; Injection Bayer Hlthcare Labeling Revision
    Ultravist 300 In Plastic Container iopromide Injectable; Injection Bayer Hlthcare Labeling Revision
    Ultravist 370 iopromide Injectable; Injection Bayer Hlthcare Labeling Revision
    Venlafaxine Hydrochloride venlafaxine hydrochloride Tablet, Extended Release; Oral Osmotica Pharm Labeling Revision
    Zestoretic hydrochlorothiazide; lisinopril Tablet; Oral Astrazeneca Labeling Revision

     

    May 1, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Amevive alefacept Vial Astellas Supplement
    Dymista azelastine hydrochloride; fluticasone proprionate Spray; Nasal Meda Pharms Approval
    Elelyso taliglucerase alfa Injectable; Injection Protalix Ltd Approval
    Gabapentin gabapentin Solution; Oral Kiel Approval
    Memantine Hydrochloride memantine hydrochloride Tablet; Oral Apotex Inc Tentative Approval
    Tasigna nilotinib hydrochloride monohydrate Capsule; Oral Novartis Labeling Revision
    Testosterone Cypionate testosterone cypionate Injectable; Injection Hikma Farmaceutica Approval

     

    April 30, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Cancidas caspofungin acetate Injectable; Iv (Infusion) Merck Approval
    Ibandronate Sodium ibandronate sodium Tablet; Oral Dr Reddys Labs Ltd Approval
    Naratriptan naratriptan hydrochloride Tablet; Oral Orchid Hlthcare Approval
    Nevirapine nevirapine Tablet, For Suspension; Oral Cipla Limited Tentative Approval
    Nevirapine nevirapine Tablet; Oral Sciegen Pharm Inc. Tentative Approval
    Pramipexole Dihydrochloride pramipexole dihydrochloride Tablet; Oral Apotex Inc Approval
    Regranex becaplermin Gel; Topical Omj Pharmaceuticals Approval
    Tinidazole tinidazole Tablet; Oral Roxane Approval
    Tinidazole tinidazole Tablet; Oral Novel Labs Inc Approval

     

    April 27, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Atacand candesartan cilexetil Tablet; Oral Astrazeneca Labeling Revision
    Celecoxib celecoxib Capsule; Oral Teva Pharms Tentative Approval
    Levaquin levofloxacin Tablet; Oral Janssen Pharms Efficacy Supplement with Clinical Data to Support
    Levaquin levofloxacin Injectable; Injection Janssen Pharms Efficacy Supplement with Clinical Data to Support
    Levaquin levofloxacin Solution; Oral Janssen Pharms Efficacy Supplement with Clinical Data to Support
    Levaquin In Dextrose 5% In Plastic Container levofloxacin Injectable; Injection Janssen Pharms Efficacy Supplement with Clinical Data to Support
    Levemir insulin detemir recombinant Injectable; Subcutaneous Novo Nordisk Inc Efficacy Supplement with Clinical Data to Support
    Lexiva fosamprenavir calcium Tablet; Oral Viiv Hlthcare Efficacy Supplement with Clinical Data to Support
    Lexiva fosamprenavir calcium Suspension; Oral Viiv Hlthcare Efficacy Supplement with Clinical Data to Support
    Pradaxa dabigatran etexilate mesylate Capsule; Oral Boehringer Ingelheim Labeling Revision
    Prolia denosumab Injectable; Subcutaneous Amgen Supplement
    Stendra avanafil Tablet, Tablet; Oral Vivus Approval
    Xgeva denosumab Injectable; Subcutaneous Amgen Supplement

     

    April 26, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Afinitor everolimus Tablet; Oral Novartis Labeling Revision
    Altoprev lovastatin Tablet, Extended Release; Oral Andrx Labs Llc Labeling Revision
    Androderm testosterone Film, Extended Release; Transdermal Watson Labs Labeling Revision
    Latuda lurasidone hydrochloride Tablet; Oral Sunovion Efficacy Supplement with Clinical Data to Support
    Latuda lurasidone hydrochloride Tablet; Oral Sunovion Labeling Revision
    Ventavis iloprost Solution; Inhalation Actelion Pharms Ltd Labeling Revision
    Votrient pazopanib hydrochloride Tablet; Oral Glaxosmithkline Labeling Revision
    Votrient pazopanib hydrochloride Tablet; Oral Glaxosmithkline New or Modified Indication
    Zortress everolimus Tablet; Oral Novartis Labeling Revision

     

    April 25, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Valturna aliskiren hemifumarate; valsartan Tablet; Oral Novartis Labeling Revision

     

    April 24, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Atorvastatin Calcium atorvastatin calcium Tablet; Oral Apotex Inc Tentative Approval
    Kalbitor ecallantide Injectable; Injection Dyax Corp. Supplement
    Prandimet metformin hydrochloride; repaglinide Tablet; Oral Novo Nordisk Inc Labeling Revision

     

    April 23, 2012

    Drug Name Active Ingredient Dosage Form/Route Sponsor Submission Type
    Cefazolin and Dextrose cefazolin sodium Injectable; Injection B Braun Labeling Revision
    Lamisil terbinafine hydrochloride Tablet; Oral Novartis Labeling Revision
    Lamisil terbinafine hydrochloride Granule; Oral Novartis Labeling Revision
    Olanzapine olanzapine Tablet; Oral Dr Reddys Labs Ltd Approval
    Olanzapine olanzapine Tablet; Oral Dr Reddys Labs Ltd Approval
    Olanzapine olanzapine Tablet; Oral Mylan Approval
    Olanzapine olanzapine Tablet; Oral Apotex Inc Approval
    Olanzapine olanzapine Tablet; Oral Sun Pharm Inds Approval
    Olanzapine olanzapine Tablet; Oral Torrent Pharms Ltd Approval
    Olanzapine olanzapine Tablet; Oral Aurobindo Pharma Ltd Approval
    Olanzapine olanzapine Tablet; Oral Orchid Hlthcare Approval
    Prevacid 24 Hr lansoprazole Capsule, Delayed Rel Pellets; Oral Novartis Labeling Revision

     

    -
    -